You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePhenytoin
Accession NumberDB00252  (APRD00241)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionAn anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. [PubChem]
Structure
Thumb
Synonyms
5,5-Diphenyl-imidazolidine-2,4-dione
5,5-diphenylimidazolidine-2,4-dione
5,5-diphenyltetrahydro-1H-2,4-imidazoledione
5,5-Diphenyltetrahydro-1H-2,4-imidazoledione
Diphenylhydantoin
Fenitoina
Phentytoin
Phenytoine
Phenytoinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dilantin - 100mgcapsule100 mgoralPfizer Canada Inc1951-12-31Not applicableCanada
Dilantin - 30mgcapsule30 mgoralPfizer Canada Inc1951-12-31Not applicableCanada
Dilantin Infatabstablet50 mgoralPfizer Canada Inc1952-12-31Not applicableCanada
Dilantin Inj 50mg/mlliquid250 mgintramuscular; intravenousParke Davis Division, Warner Lambert Canada Inc.1972-12-311996-09-10Canada
Dilantin-125suspension125 mg/5mLoralParke Davis Div Of Pfizer Inc1953-01-06Not applicableUs
Dilantin-125 Suspensionsuspension125 mgoralPfizer Canada Inc1953-12-31Not applicableCanada
Dilantin-30 Suspensionsuspension30 mgoralPfizer Canada Inc1968-12-31Not applicableCanada
Novo-phenytoin Cap 100mgcapsule100 mgoralNovopharm Limited1966-12-31Not applicableCanada
Phenytoinsuspension125 mg/5mLoralGreenstone LLC2012-10-09Not applicableUs
Phenytoin Sodium Inj 50mg/ml USPsolution50 mgintramuscular; intravenousHospira Healthcare Corporation1989-12-31Not applicableCanada
Phenytoin Sodium Injection USPliquid50 mgintramuscular; intravenousSandoz Canada Incorporated1988-12-31Not applicableCanada
Phenytoin Sodium Injection, USPsolution50 mgintramuscular; intravenousSterimax Inc2015-03-12Not applicableCanada
Taro-phenytoinsuspension125 mgoralTaro Pharmaceuticals Inc2005-05-03Not applicableCanada
Tremytoine Inj 50mg/mlliquid50 mgintramuscular; intravenousOmega Laboratories Ltd1992-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dilantincapsule, extended release100 mg/1oralAphena Pharma Solutions Tennessee, Inc.1976-08-27Not applicableUs
Dilantincapsule, extended release100 mg/1oralA S Medication Solutions Llc1976-08-27Not applicableUs
Dilantincapsule, extended release30 mg/1oralAvera Mc Kennan Hospital2015-09-14Not applicableUs
Dilantincapsule, extended release30 mg/1oralPhysicians Total Care, Inc.2003-08-19Not applicableUs
Dilantincapsule, extended release30 mg/1oralREMEDYREPACK INC.2010-11-30Not applicableUs
Dilantincapsule, extended release100 mg/1oralParke Davis Div Of Pfizer Inc1976-08-27Not applicableUs
Dilantintablet, chewable50 mg/1oralREMEDYREPACK INC.2011-08-18Not applicableUs
Dilantincapsule, extended release30 mg/1oralREMEDYREPACK INC.2011-05-05Not applicableUs
Dilantincapsule, extended release100 mg/1oralCardinal Health1976-08-27Not applicableUs
Dilantincapsule, extended release30 mg/1oralParke Davis Div Of Pfizer Inc1976-08-27Not applicableUs
Dilantincapsule, extended release100 mg/1oralA S Medication Solutions Llc1976-08-27Not applicableUs
Dilantincapsule100 mg/1oralREMEDYREPACK INC.2011-07-08Not applicableUs
Dilantincapsule, extended release30 mg/1oralCarilion Materials Management1976-08-27Not applicableUs
Dilantincapsule, extended release30 mg/1oralKAISER FOUNDATION HOSPITALS2009-09-20Not applicableUs
Dilantincapsule, extended release100 mg/1oralPhysicians Total Care, Inc.1995-01-27Not applicableUs
Dilantincapsule, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC1976-08-27Not applicableUs
Dilantin Infatabstablet, chewable50 mg/1oralParke Davis Div Of Pfizer Inc1979-02-26Not applicableUs
Dilantin Infatabstablet, chewable50 mg/1oralCardinal Health1979-02-26Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralREMEDYREPACK INC.2012-12-26Not applicableUs
Extended Phenytoin Sodiumcapsule, extended release100 mg/1oralMarlex Pharmaceuticals Inc2015-08-01Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralTYA Pharmaceuticals2008-01-30Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralREMEDYREPACK INC.2013-04-09Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralAurobindo Pharma Limited2015-06-10Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralREMEDYREPACK INC.2014-08-25Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralAmerican Health Packaging2013-07-19Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralPd Rx Pharmaceuticals, Inc.2008-01-30Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralWockhardt Limited2008-01-30Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralPd Rx Pharmaceuticals, Inc.2009-12-16Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralAmneal Pharmaceuticals of New York, LLC2009-12-16Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralWockhardt USA LLC.2008-01-30Not applicableUs
Extended Phenytoin Sodiumcapsule100 mg/1oralMajor Pharmaceuticals2009-12-16Not applicableUs
Phenytekcapsule, extended release300 mg/1oralClinical Solutions Wholesale2001-12-10Not applicableUs
Phenytekcapsule, extended release200 mg/1oralMylan Pharmaceuticals Inc.2001-12-10Not applicableUs
Phenytekcapsule, extended release300 mg/1oralMylan Pharmaceuticals Inc.2001-12-10Not applicableUs
Phenytointablet, chewable50 mg/1oralMylan Pharmaceuticals Inc.2012-12-26Not applicableUs
Phenytointablet, chewable50 mg/1oralCardinal Health2012-12-26Not applicableUs
Phenytointablet, chewable50 mg/1oralAmerican Health Packaging2015-09-01Not applicableUs
Phenytointablet, chewable50 mg/1oralMylan Institutional Inc.2012-12-18Not applicableUs
Phenytointablet, chewable50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-12-26Not applicableUs
Phenytointablet, chewable50 mg/1oralTaro Pharmaceuticals U.S.A., Inc2014-04-17Not applicableUs
Phenytoinsuspension125 mg/5mLoralPhysicians Total Care, Inc.2006-12-19Not applicableUs
Phenytoinsuspension125 mg/5mLoralVista Pharm Inc.2010-05-10Not applicableUs
Phenytoinsuspension100 mg/4mLoralPrecision Dose Inc.2004-02-052016-02-05Us
Phenytoinsuspension125 mg/5mLoralAtlantic Biologicals Corps2002-06-24Not applicableUs
Phenytoinsuspension125 mg/5mLoralLehigh Valley Technologies, Inc.2014-04-01Not applicableUs
Phenytointablet, chewable50 mg/1oralCore Pharma, Llc2016-02-28Not applicableUs
Phenytoinsuspension125 mg/5mLoralVista Pharm Inc.2005-08-18Not applicableUs
Phenytoinsuspension125 mg/5mLoralMorton Grove Pharmaceuticals, Inc.2002-06-24Not applicableUs
Phenytoinsuspension125 mg/5mLoralActavis Mid Atlantic LLC2009-03-02Not applicableUs
Phenytoinsuspension125 mg/5mLoralAtlantic Biologicals Corps2004-04-08Not applicableUs
Phenytoinsuspension125 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2004-04-08Not applicableUs
Phenytoin ERcapsule100 mg/1oralSTAT Rx USA LLC2009-11-20Not applicableUs
Phenytoin Infatabstablet, chewable50 mg/1oralGreenstone LLC2012-12-27Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Phenytoin Sodiuminjection50 mg/mLintravenousCardinal Health2006-10-01Not applicableUs
Phenytoin Sodiuminjection50 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp.1975-07-16Not applicableUs
Phenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-20Not applicableUs
Phenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousCardinal Health2011-05-02Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralSun Pharmaceutical Industries Limited2006-12-12Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralRebel Distributors Corp2006-09-05Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2006-09-05Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralMylan Pharmaceuticals Inc.1999-01-05Not applicableUs
Phenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousHospira, Inc.1987-03-17Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralTYA Pharmaceuticals2006-09-05Not applicableUs
Phenytoin Sodiuminjection50 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp.1975-07-16Not applicableUs
Phenytoin Sodiuminjection, solution250 mg/5mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc.2011-08-30Not applicableUs
Phenytoin Sodiuminjection50 mg/mLintramuscular; intravenousCardinal Health1975-07-16Not applicableUs
Phenytoin Sodiumcapsule, extended release300 mg/1oralSun Pharmaceutical Industries Limited2008-06-30Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralMc Kesson Contract Packaging2011-09-19Not applicableUs
Phenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousX Gen Pharmaceuticals, Inc.2011-05-02Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralREMEDYREPACK INC.2013-08-27Not applicableUs
Phenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousHospira, Inc.1987-12-18Not applicableUs
Phenytoin Sodiumcapsule100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralMylan Institutional Inc.1999-05-01Not applicableUs
Phenytoin Sodiuminjection50 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp.1975-07-16Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2006-12-12Not applicableUs
Phenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralUpsher Smith Laboratories, Inc.2006-09-05Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralCardinal Health2011-01-28Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralbryant ranch prepack2011-07-07Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralREMEDYREPACK INC.2013-03-20Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralPhysicians Total Care, Inc.2007-07-12Not applicableUs
Phenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralCardinal Health2006-09-05Not applicableUs
Phenytoin Sodiumcapsule, extended release200 mg/1oralSun Pharmaceutical Industries Limited2008-06-30Not applicableUs
Phenytoin Sodiumcapsule, extended release100 mg/1oralClinical Solutions Wholesale2006-12-12Not applicableUs
Phenytoin Sodiuminjection50 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp.1975-07-16Not applicableUs
Phenytoin Sodiuminjection, solution50 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2011-04-12Not applicableUs
Phenytoin Sodiuminjection50 mg/mLintravenousCardinal Health2006-10-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Epanutin Pfizer
EptoinNot Available
Brand mixtures
NameLabellerIngredients
Dilantin W Phenobarbital 15mgParke Davis Division, Warner Lambert Canada Inc.
Dilantin W Phenobarbital 30mg CapParke Davis Division, Warner Lambert Canada Inc.
Salts
Name/CASStructureProperties
Phenytoin sodium
Thumb
  • InChI Key: FJPYVLNWWICYDW-UHFFFAOYSA-M
  • Monoisotopic Mass: 274.071822281
  • Average Mass: 274.2498
DBSALT000139
Categories
UNII6158TKW0C5
CAS number57-41-0
WeightAverage: 252.268
Monoisotopic: 252.089877638
Chemical FormulaC15H12N2O2
InChI KeyInChIKey=CXOFVDLJLONNDW-UHFFFAOYSA-N
InChI
InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)
IUPAC Name
5,5-diphenylimidazolidine-2,4-dione
SMILES
O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzolidines
Sub ClassImidazolidines
Direct ParentPhenylhydantoins
Alternative Parents
Substituents
  • 5-phenylhydantoin
  • Diphenylmethane
  • Phenylimidazolidine
  • 5-monosubstituted hydantoin
  • Ureide
  • Benzenoid
  • Monocyclic benzene moiety
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
PharmacodynamicsPhenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. Phenytoin acts to dampen the unwanted, runaway brain activity seen in seizure by reducing electrical conductance among brain cells. It lacks the sedation effects associated with phenobarbital. There are some indications that phenytoin has other effects, including anxiety control and mood stabilization, although it has never been approved for those purposes by the FDA. Phenytoin is primarily metabolized by CYP2C9.
Mechanism of actionPhenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses. Loss of post-tetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas.
Related Articles
AbsorptionBioavailability 70-100% oral, 24.4% rectal. Rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours.
Volume of distributionNot Available
Protein bindingHighly protein bound, 90%
Metabolism

Primarily hepatic. The majority of the dose (up to 90%) is metabolized to 5-(4'-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). This metabolite undergoes further glucuronidation and is excreted into the urine. CYP2C19 and CYP2C9 catalyze the aforementioned reaction.

SubstrateEnzymesProduct
Phenytoin
3',4'-DihydrodiolDetails
Phenytoin
3'-HPPHDetails
Phenytoin
4'-HPPHDetails
Phenytoin
Phenytoin arene-oxideDetails
Phenytoin
Not Available
Phenytoin catecholDetails
Phenytoin
Not Available
Phenytoin quinoneDetails
Phenytoin catechol
Phenytoin methylcatecholDetails
Phenytoin arene-oxide
Phenytoin dihydrodiolDetails
Phenytoin arene-oxide
Not Available
HydroxyphenytoinDetails
Hydroxyphenytoin
Phenytoin catecholDetails
Phenytoin catechol
Phenytoin quinoneDetails
Hydroxyphenytoin
Hydroxyphenytoin-O-glucuronideDetails
3'-HPPH
3',4'-diHPPHDetails
4'-HPPH
3',4'-diHPPHDetails
Route of eliminationMost of the drug is excreted in the bile as inactive metabolites which are then reabsorbed from the intestinal tract and excreted in the urine. Urinary excretion of phenytoin and its metabolites occurs partly with glomerular filtration but, more importantly, by tubular secretion.
Half life22 hours (range of 7 to 42 hours)
ClearanceNot Available
ToxicityOral, mouse: LD50 = 150 mg/kg; Oral, rat: LD50 = 1635 mg/kg. Symptoms of overdose include coma, difficulty in pronouncing words correctly, involuntary eye movement, lack of muscle coordination, low blood pressure, nausea, sluggishness, slurred speech, tremors, and vomiting.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fosphenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00326
Fosphenytoin (Antiarrhythmic) Metabolism PathwayDrug metabolismSMP00618
Phenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00327
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712
rs1057910 CYP2C9*1C AllelePoor drug metabolizer, lower dose requirements15805193
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs1045642 MDR1*TT Allele (C3435T)Increased phenytoin effects due to higher plasma phenytoin levels11908757
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9909
Blood Brain Barrier+0.976
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5593
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.987
Renal organic cation transporterNon-inhibitor0.8995
CYP450 2C9 substrateNon-substrate0.733
CYP450 2D6 substrateSubstrate0.8911
CYP450 3A4 substrateNon-substrate0.7591
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.8304
CYP450 2D6 inhibitorNon-inhibitor0.935
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8994
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.855
BiodegradationNot ready biodegradable0.992
Rat acute toxicity2.1567 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9793
hERG inhibition (predictor II)Non-inhibitor0.8916
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Parke davis div warner lambert co
  • Actavis mid atlantic llc
  • Taro pharmaceutical industries ltd
  • Vistapharm inc
  • Wockhardt eu operations (swiss) ag
  • Pfizer pharmaceuticals ltd
  • Lannett co inc
  • Amneal pharmaceuticals ny llc
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Sun pharmaceutical industries ltd
  • Wockhardt ltd
  • Wockhardt usa inc
  • Watson laboratories inc
  • Pharmeral inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Parke davis pharmaceutical research div warner lambert co
  • App pharmaceuticals llc
  • Baxter healthcare corp
  • Hikma farmaceutica (portugal) sa
  • Hospira inc
  • Marsam pharmaceuticals llc
  • Pharmaforce inc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Warner chilcott div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral30 mg/1
Capsuleoral100 mg
Capsuleoral30 mg
Tabletoral50 mg
Tablet, chewableoral50 mg/1
Liquidintramuscular; intravenous250 mg
Capsuleoral
Suspensionoral125 mg/5mL
Suspensionoral125 mg
Suspensionoral30 mg
Capsuleoral100 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral300 mg/1
Suspensionoral100 mg/4mL
Injectionintramuscular; intravenous50 mg/mL
Injectionintravenous50 mg/mL
Injection, solutionintramuscular; intravenous250 mg/5mL
Injection, solutionintramuscular; intravenous50 mg/mL
Solutionintramuscular; intravenous50 mg
Liquidintramuscular; intravenous50 mg
Prices
Unit descriptionCostUnit
Dilantin 125 mg/5ml Suspension 237ml Bottle69.28USD bottle
Phenytoin Sodium 50 mg/ml2.64USD ml
Phenytek 300 mg capsule1.47USD capsule
Phenytoin sod ext 300 mg capsule1.2USD capsule
Phenytoin sodium powder1.16USD g
Phenytek 200 mg capsule0.98USD capsule
Phenytoin 50 mg/ml ampul0.96USD ml
Phenytoin sod ext 200 mg capsule0.8USD capsule
Phenytoin 50 mg/ml vial0.67USD ml
Phenytoin 100 mg/2 ml vial0.6USD ml
Dilantin Infatabs 50 mg Chew Tabs0.6USD tab
Dilantin 100 mg capsule0.51USD capsule
Phenytoin 100 mg/4 ml susp0.48USD ml
Dilantin 30 mg capsule0.46USD capsule
Phenytoin 250 mg/5 ml vial0.45USD ml
Dilantin 50 mg infatab0.44USD each
Dilantin 100 mg kapseal0.39USD each
Dilantin 30 mg kapseal0.39USD each
Phenytoin Sodium Extended 100 mg capsule0.36USD capsule
Phenytoin sod ext 100 mg capsule0.34USD capsule
Phenytoin powder0.23USD g
Phenytoin 125 mg/5ml Suspension0.15USD ml
Dilantin Infatabs 50 mg Chewable Tablet0.08USD tablet
Dilantin 100 mg Capsule0.08USD capsule
Dilantin 30 mg Capsule0.06USD capsule
Dilantin-125 25 mg/ml Suspension0.05USD ml
Dilantin-30 6 mg/ml Suspension0.04USD ml
Taro-Phenytoin 25 mg/ml Suspension0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point286 °CPhysProp
water solubility32 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.47HANSCH,C ET AL. (1995)
Caco2 permeability-4.57ADME Research, USCD
pKa8.33SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0711 mg/mLALOGPS
logP2.26ALOGPS
logP2.15ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)9.47ChemAxon
pKa (Strongest Basic)-9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity70.18 m3·mol-1ChemAxon
Polarizability25.48 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.46 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0f89-4940000000-2a0dda513d9f63dc6610View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Mahdi B. Fawzi, Anne K. Taylor, “Parenteral phenytoin preparations.” U.S. Patent US4642316, issued April, 1981.

US4642316
General References
  1. Link [Link]
External Links
ATC CodesN03AB02N03AB52
AHFS Codes
  • 28:12.12
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe serum concentration of Phenytoin can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe serum concentration of Phenytoin can be increased when it is combined with 2-mercaptobenzothiazole.
3,4-MethylenedioxyamphetamineThe serum concentration of Phenytoin can be decreased when it is combined with 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineThe serum concentration of Phenytoin can be decreased when it is combined with 3,4-Methylenedioxymethamphetamine.
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Phenytoin.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Phenytoin.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Phenytoin.
AbirateroneThe serum concentration of Phenytoin can be increased when it is combined with Abiraterone.
AceclofenacThe metabolism of Aceclofenac can be increased when combined with Phenytoin.
AcenocoumarolPhenytoin may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Phenytoin.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Phenytoin.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Phenytoin.
AcetaminophenThe serum concentration of Phenytoin can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Phenytoin.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be increased when combined with Phenytoin.
AdinazolamThe metabolism of Adinazolam can be increased when combined with Phenytoin.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Phenytoin.
AfatinibThe serum concentration of Phenytoin can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenytoin.
AlbendazoleThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Phenytoin resulting in a loss in efficacy.
AlbendazoleThe serum concentration of Phenytoin can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Phenytoin.
AldosteroneThe serum concentration of Phenytoin can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Phenytoin can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Phenytoin.
AlfentanilThe serum concentration of Phenytoin can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Phenytoin is combined with Alfentanil.
AlfuzosinThe metabolism of Alfuzosin can be increased when combined with Phenytoin.
AliskirenThe metabolism of Aliskiren can be increased when combined with Phenytoin.
AllylestrenolThe metabolism of Allylestrenol can be increased when combined with Phenytoin.
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Phenytoin.
AlogliptinThe metabolism of Alogliptin can be increased when combined with Phenytoin.
AlosetronThe metabolism of Alosetron can be increased when combined with Phenytoin.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Phenytoin.
AlprazolamThe serum concentration of Phenytoin can be increased when it is combined with Alprazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Alprazolam.
AmantadineThe serum concentration of Phenytoin can be increased when it is combined with Amantadine.
AmbrisentanThe metabolism of Ambrisentan can be increased when combined with Phenytoin.
AmbroxolThe metabolism of Ambroxol can be increased when combined with Phenytoin.
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Phenytoin.
Aminohippuric acidThe serum concentration of Phenytoin can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Phenytoin.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Phenytoin.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Phenytoin.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Phenytoin.
AmitriptylineThe serum concentration of Phenytoin can be increased when it is combined with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Amitriptyline.
AmlodipineThe metabolism of Amlodipine can be increased when combined with Phenytoin.
AmlodipineThe serum concentration of Phenytoin can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Phenytoin.
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Phenytoin.
AmorolfineThe serum concentration of Phenytoin can be increased when it is combined with Amorolfine.
AmoxapineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Amoxapine.
AmoxicillinThe metabolism of Amoxicillin can be increased when combined with Phenytoin.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Phenytoin.
AmphetamineThe serum concentration of Phenytoin can be decreased when it is combined with Amphetamine.
Amphotericin BThe serum concentration of Phenytoin can be increased when it is combined with Amphotericin B.
AmprenavirThe metabolism of Amprenavir can be increased when combined with Phenytoin.
AmprenavirThe serum concentration of Phenytoin can be decreased when it is combined with Amprenavir.
AmrinoneThe serum concentration of Phenytoin can be increased when it is combined with Amrinone.
AmsacrineThe serum concentration of Phenytoin can be increased when it is combined with Amsacrine.
AN2690The serum concentration of Phenytoin can be increased when it is combined with AN2690.
AnidulafunginThe serum concentration of Phenytoin can be increased when it is combined with Anidulafungin.
AntipyrineThe metabolism of Antipyrine can be increased when combined with Phenytoin.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Phenytoin.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Phenytoin.
AprepitantThe serum concentration of Phenytoin can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be increased when combined with Phenytoin.
Arachidonic AcidThe metabolism of Arachidonic Acid can be increased when combined with Phenytoin.
ArformoterolThe metabolism of Arformoterol can be increased when combined with Phenytoin.
ArgatrobanThe metabolism of Argatroban can be increased when combined with Phenytoin.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenytoin.
ArmodafinilThe metabolism of Phenytoin can be decreased when combined with Armodafinil.
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenytoin resulting in a loss in efficacy.
ArtemetherThe serum concentration of Phenytoin can be increased when it is combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Phenytoin.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Phenytoin.
AstemizoleThe metabolism of Astemizole can be increased when combined with Phenytoin.
AstemizoleThe serum concentration of Phenytoin can be increased when it is combined with Astemizole.
AtazanavirThe metabolism of Atazanavir can be increased when combined with Phenytoin.
AtazanavirThe serum concentration of Phenytoin can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Phenytoin can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Phenytoin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Phenytoin.
AtorvastatinThe serum concentration of Phenytoin can be increased when it is combined with Atorvastatin.
Atracurium besylatePhenytoin may decrease the neuromuscular blocking activities of Atracurium besylate.
AvanafilThe metabolism of Avanafil can be increased when combined with Phenytoin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Phenytoin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Phenytoin.
AzelastinePhenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Phenytoin can be increased when it is combined with Azelastine.
AzelnidipineThe serum concentration of Phenytoin can be increased when it is combined with Azelnidipine.
AzimilideThe serum concentration of Phenytoin can be increased when it is combined with Azimilide.
AzithromycinThe metabolism of Azithromycin can be increased when combined with Phenytoin.
AzithromycinThe serum concentration of Phenytoin can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Phenytoin.
Bafilomycin A1The serum concentration of Phenytoin can be increased when it is combined with Bafilomycin A1.
BanoxantroneThe metabolism of Banoxantrone can be increased when combined with Phenytoin.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Phenytoin.
BarnidipineThe serum concentration of Phenytoin can be increased when it is combined with Barnidipine.
BazedoxifeneThe serum concentration of Bazedoxifene can be decreased when it is combined with Phenytoin.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Phenytoin.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Phenytoin.
BenidipineThe serum concentration of Phenytoin can be increased when it is combined with Benidipine.
BenzatropineThe metabolism of Benzatropine can be increased when combined with Phenytoin.
BenzocaineThe serum concentration of Phenytoin can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Benzocaine.
Benzoic AcidThe serum concentration of Phenytoin can be increased when it is combined with Benzoic Acid.
BenzphetamineThe serum concentration of Phenytoin can be decreased when it is combined with Benzphetamine.
BenzphetamineThe metabolism of Benzphetamine can be increased when combined with Phenytoin.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Phenytoin.
BepridilThe serum concentration of Phenytoin can be increased when it is combined with Bepridil.
BeraprostThe metabolism of Beraprost can be increased when combined with Phenytoin.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Phenytoin.
BexaroteneThe serum concentration of Phenytoin can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be increased when combined with Phenytoin.
BezafibrateThe metabolism of Bezafibrate can be increased when combined with Phenytoin.
BicalutamideThe metabolism of Bicalutamide can be increased when combined with Phenytoin.
BifonazoleThe serum concentration of Phenytoin can be increased when it is combined with Bifonazole.
BiperidenThe serum concentration of Phenytoin can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be increased when combined with Phenytoin.
BleomycinThe serum concentration of Phenytoin can be decreased when it is combined with Bleomycin.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Phenytoin.
BoceprevirThe metabolism of Phenytoin can be decreased when combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Phenytoin.
BortezomibThe metabolism of Phenytoin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Phenytoin can be decreased when it is combined with Bosentan.
BosentanThe metabolism of Bosentan can be increased when combined with Phenytoin.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Phenytoin.
BosutinibThe serum concentration of Phenytoin can be increased when it is combined with Bosutinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenytoin.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Phenytoin is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
BrimonidineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Brimonidine.
BrinzolamideThe metabolism of Brinzolamide can be increased when combined with Phenytoin.
BromazepamThe serum concentration of Phenytoin can be increased when it is combined with Bromazepam.
BromazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Bromazepam.
BromocriptineThe metabolism of Bromocriptine can be increased when combined with Phenytoin.
BromocriptineThe serum concentration of Phenytoin can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Phenytoin.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Phenytoin.
BumetanidePhenytoin may decrease the diuretic activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenytoin.
BuprenorphineThe serum concentration of Phenytoin can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be increased when combined with Phenytoin.
BuspironeThe serum concentration of Phenytoin can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Phenytoin is combined with Buspirone.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Phenytoin.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenytoin.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Phenytoin.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Phenytoin.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Phenytoin.
ButenafineThe serum concentration of Phenytoin can be increased when it is combined with Butenafine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Phenytoin.
ButoconazoleThe serum concentration of Phenytoin can be increased when it is combined with Butoconazole.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenytoin.
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Phenytoin.
CabazitaxelThe serum concentration of Phenytoin can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be increased when combined with Phenytoin.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Phenytoin.
CaffeineThe metabolism of Caffeine can be increased when combined with Phenytoin.
CaffeineThe serum concentration of Phenytoin can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be increased when combined with Phenytoin.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.
CanagliflozinThe serum concentration of Phenytoin can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Phenytoin can be increased when it is combined with Candesartan.
CandesartanThe metabolism of Candesartan can be increased when combined with Phenytoin.
CandicidinThe serum concentration of Phenytoin can be increased when it is combined with Candicidin.
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Phenytoin.
CapecitabineThe serum concentration of Phenytoin can be increased when it is combined with Capecitabine.
CaptoprilThe serum concentration of Phenytoin can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Phenytoin can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Phenytoin.
CariprazineThe metabolism of Cariprazine can be increased when combined with Phenytoin.
CarisoprodolThe risk or severity of adverse effects can be increased when Phenytoin is combined with Carisoprodol.
CarvedilolThe metabolism of Carvedilol can be increased when combined with Phenytoin.
CarvedilolThe serum concentration of Phenytoin can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Phenytoin.
CaspofunginThe serum concentration of Phenytoin can be increased when it is combined with Caspofungin.
CefazolinThe protein binding of Phenytoin can be decreased when combined with Cefazolin.
CelecoxibThe metabolism of Celecoxib can be increased when combined with Phenytoin.
CeliprololThe metabolism of Celiprolol can be increased when combined with Phenytoin.
CephalexinThe metabolism of Cephalexin can be increased when combined with Phenytoin.
CeritinibThe serum concentration of Phenytoin can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Phenytoin.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Phenytoin.
CeruleninThe serum concentration of Phenytoin can be increased when it is combined with Cerulenin.
CetirizineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be increased when combined with Phenytoin.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be increased when combined with Phenytoin.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Phenytoin.
ChloramphenicolThe metabolism of Phenytoin can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe serum concentration of Phenytoin can be increased when it is combined with Chlordiazepoxide.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Phenytoin is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Phenytoin.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenytoin.
ChloroquineThe metabolism of Chloroquine can be increased when combined with Phenytoin.
ChloroquineThe serum concentration of Phenytoin can be increased when it is combined with Chloroquine.
ChloroxineThe serum concentration of Phenytoin can be increased when it is combined with Chloroxine.
ChlorphenamineThe serum concentration of Phenytoin can be increased when it is combined with Chlorphenamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Chlorphenamine.
ChlorphentermineThe serum concentration of Phenytoin can be decreased when it is combined with Chlorphentermine.
ChlorpromazineThe serum concentration of Phenytoin can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Phenytoin can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Phenytoin.
ChlorprothixeneThe serum concentration of Phenytoin can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Cholecalciferol can be increased when combined with Phenytoin.
CholesterolThe serum concentration of Phenytoin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Phenytoin can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Phenytoin.
CiclopiroxThe serum concentration of Phenytoin can be increased when it is combined with Ciclopirox.
CilazaprilThe serum concentration of Phenytoin can be increased when it is combined with Cilazapril.
CilnidipineThe serum concentration of Phenytoin can be increased when it is combined with Cilnidipine.
CilostazolThe metabolism of Cilostazol can be increased when combined with Phenytoin.
CimetidineThe serum concentration of Phenytoin can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be increased when combined with Phenytoin.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenytoin.
CinnarizineThe serum concentration of Phenytoin can be increased when it is combined with Cinnarizine.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Phenytoin.
CiprofloxacinThe therapeutic efficacy of Phenytoin can be decreased when used in combination with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be increased when combined with Phenytoin.
CitalopramThe risk or severity of adverse effects can be increased when Phenytoin is combined with Citalopram.
CitalopramThe serum concentration of Phenytoin can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Phenytoin.
ClarithromycinThe serum concentration of Phenytoin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Phenytoin can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clemastine.
ClevidipineThe serum concentration of Phenytoin can be increased when it is combined with Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clidinium.
ClindamycinThe metabolism of Clindamycin can be increased when combined with Phenytoin.
ClobazamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clobazam.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Phenytoin.
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Phenytoin.
ClofazimineThe metabolism of Clofazimine can be increased when combined with Phenytoin.
ClofazimineThe serum concentration of Phenytoin can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be increased when combined with Phenytoin.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Phenytoin.
ClomipramineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clomipramine.
ClomipramineThe serum concentration of Phenytoin can be increased when it is combined with Clomipramine.
ClonazepamThe serum concentration of Phenytoin can be increased when it is combined with Clonazepam.
ClonazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clonidine.
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Phenytoin.
ClorazepateThe serum concentration of Phenytoin can be increased when it is combined with Clorazepate.
ClorazepateThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clorazepate.
ClotiazepamThe metabolism of Clotiazepam can be increased when combined with Phenytoin.
ClotrimazoleThe metabolism of Phenytoin can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Phenytoin.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenytoin.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Phenytoin.
CobicistatThe serum concentration of Phenytoin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Phenytoin.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Phenytoin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Phenytoin.
Coenzyme Q10The serum concentration of Coenzyme Q10 can be decreased when it is combined with Phenytoin.
ColchicineThe metabolism of Colchicine can be increased when combined with Phenytoin.
ColchicineThe serum concentration of Phenytoin can be increased when it is combined with Colchicine.
ColesevelamThe serum concentration of Phenytoin can be decreased when it is combined with Colesevelam.
ColforsinThe serum concentration of Phenytoin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Phenytoin can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be increased when combined with Phenytoin.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be increased when combined with Phenytoin.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Phenytoin.
CosyntropinCosyntropin may increase the hepatotoxic activities of Phenytoin.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Phenytoin.
CrizotinibThe metabolism of Phenytoin can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenytoin.
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Phenytoin.
CyclophosphamideThe serum concentration of Phenytoin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Phenytoin.
CyproheptadineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Cyproheptadine.
CytarabineThe metabolism of Cytarabine can be increased when combined with Phenytoin.
DabrafenibThe serum concentration of Phenytoin can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be increased when combined with Phenytoin.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Phenytoin.
DaclatasvirThe serum concentration of Phenytoin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Phenytoin can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dantrolene.
DapagliflozinThe metabolism of Dapagliflozin can be increased when combined with Phenytoin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenytoin.
DapoxetineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dapoxetine.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Phenytoin.
DapsoneThe metabolism of Dapsone can be increased when combined with Phenytoin.
DarifenacinThe metabolism of Darifenacin can be increased when combined with Phenytoin.
DarodipineThe serum concentration of Phenytoin can be increased when it is combined with Darodipine.
DarunavirThe serum concentration of Phenytoin can be decreased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be increased when combined with Phenytoin.
DasabuvirThe metabolism of Dasabuvir can be increased when combined with Phenytoin.
DasatinibThe serum concentration of Phenytoin can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Phenytoin.
DaunorubicinThe metabolism of Daunorubicin can be increased when combined with Phenytoin.
DaunorubicinThe serum concentration of Phenytoin can be decreased when it is combined with Daunorubicin.
Decanoic AcidThe serum concentration of Phenytoin can be increased when it is combined with Decanoic Acid.
DeferasiroxThe serum concentration of Phenytoin can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Phenytoin.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Phenytoin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Phenytoin.
DelavirdineThe metabolism of Phenytoin can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Phenytoin.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenytoin.
DesipramineThe serum concentration of Phenytoin can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Desipramine.
DesloratadineThe serum concentration of Phenytoin can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Phenytoin.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Phenytoin.
DesvenlafaxineThe metabolism of Desvenlafaxine can be increased when combined with Phenytoin.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Phenytoin.
DexamethasoneThe serum concentration of Phenytoin can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Phenytoin.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dexbrompheniramine.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Phenytoin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenytoin.
DexmethylphenidateThe serum concentration of Phenytoin can be increased when it is combined with Dexmethylphenidate.
DextroamphetamineThe serum concentration of Phenytoin can be decreased when it is combined with Dextroamphetamine.
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Phenytoin.
DextromethorphanThe serum concentration of Phenytoin can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenytoin.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenytoin.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Phenytoin.
DiazepamThe serum concentration of Phenytoin can be increased when it is combined with Diazepam.
DiazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Diazepam.
DiazoxideThe serum concentration of Phenytoin can be decreased when it is combined with Diazoxide.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Phenytoin.
DiclofenacThe serum concentration of Phenytoin can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Phenytoin.
DicoumarolPhenytoin may increase the anticoagulant activities of Dicoumarol.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Phenytoin.
DifenoxinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Difenoxin.
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Phenytoin.
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Phenytoin.
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Phenytoin.
DigitoxinThe metabolism of Digitoxin can be increased when combined with Phenytoin.
DigoxinThe metabolism of Digoxin can be increased when combined with Phenytoin.
DigoxinThe serum concentration of Phenytoin can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenytoin.
DihydroergotamineThe metabolism of Dihydroergotamine can be increased when combined with Phenytoin.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Phenytoin.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenytoin.
DiltiazemThe metabolism of Diltiazem can be increased when combined with Phenytoin.
DimenhydrinateThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenytoin.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenytoin.
DipyridamoleThe serum concentration of Phenytoin can be increased when it is combined with Dipyridamole.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Phenytoin.
DisulfiramThe serum concentration of Phenytoin can be increased when it is combined with Disulfiram.
DisulfiramThe metabolism of Disulfiram can be increased when combined with Phenytoin.
DocetaxelThe metabolism of Docetaxel can be increased when combined with Phenytoin.
DofetilideThe metabolism of Dofetilide can be increased when combined with Phenytoin.
DolasetronThe metabolism of Dolasetron can be increased when combined with Phenytoin.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Phenytoin.
DomperidoneThe metabolism of Domperidone can be increased when combined with Phenytoin.
DonepezilThe metabolism of Donepezil can be increased when combined with Phenytoin.
DopamineThe metabolism of Dopamine can be increased when combined with Phenytoin.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Phenytoin.
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Phenytoin.
DotarizineThe serum concentration of Phenytoin can be increased when it is combined with Dotarizine.
DoxazosinThe serum concentration of Phenytoin can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be increased when combined with Phenytoin.
DoxepinThe serum concentration of Phenytoin can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Doxepin.
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Phenytoin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Phenytoin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Phenytoin.
DoxycyclineThe metabolism of Phenytoin can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
DoxylamineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenytoin.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Phenytoin.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Phenytoin.
DronedaroneThe metabolism of Phenytoin can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Phenytoin.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Phenytoin.
DutasterideThe metabolism of Dutasteride can be increased when combined with Phenytoin.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenytoin.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Phenytoin.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Phenytoin.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Phenytoin.
EconazoleThe serum concentration of Phenytoin can be increased when it is combined with Econazole.
EfavirenzThe serum concentration of Phenytoin can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Phenytoin is combined with Efavirenz.
EfinaconazoleThe serum concentration of Phenytoin can be increased when it is combined with Efinaconazole.
EfonidipineThe serum concentration of Phenytoin can be increased when it is combined with Efonidipine.
ElbasvirThe serum concentration of Phenytoin can be increased when it is combined with Elbasvir.
EletriptanThe metabolism of Eletriptan can be increased when combined with Phenytoin.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Phenytoin.
EltrombopagThe metabolism of Eltrombopag can be increased when combined with Phenytoin.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Phenytoin.
EnalaprilThe metabolism of Enalapril can be increased when combined with Phenytoin.
EnalaprilThe serum concentration of Phenytoin can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Phenytoin.
EnfuvirtideThe metabolism of Enfuvirtide can be increased when combined with Phenytoin.
EntacaponeThe risk or severity of adverse effects can be increased when Phenytoin is combined with Entacapone.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Phenytoin.
EperisoneThe serum concentration of Phenytoin can be increased when it is combined with Eperisone.
EpinastineThe metabolism of Epinastine can be increased when combined with Phenytoin.
EplerenoneThe metabolism of Eplerenone can be increased when combined with Phenytoin.
EpoprostenolThe metabolism of Epoprostenol can be increased when combined with Phenytoin.
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Phenytoin.
EquilinThe serum concentration of Equilin can be decreased when it is combined with Phenytoin.
ErgocalciferolThe metabolism of Ergocalciferol can be increased when combined with Phenytoin.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be increased when combined with Phenytoin.
ErgonovineThe metabolism of Ergonovine can be increased when combined with Phenytoin.
ErgonovineThe serum concentration of Phenytoin can be increased when it is combined with Ergonovine.
ErgotamineThe metabolism of Ergotamine can be increased when combined with Phenytoin.
ErgotamineThe serum concentration of Phenytoin can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Phenytoin.
ErythromycinThe metabolism of Erythromycin can be increased when combined with Phenytoin.
EscitalopramThe risk or severity of adverse effects can be increased when Phenytoin is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenytoin.
EsomeprazoleThe metabolism of Esomeprazole can be increased when combined with Phenytoin.
EstazolamThe serum concentration of Phenytoin can be increased when it is combined with Estazolam.
EstazolamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Estazolam.
EstradiolThe metabolism of Estradiol can be increased when combined with Phenytoin.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be increased when combined with Phenytoin.
EstramustineThe metabolism of Estramustine can be increased when combined with Phenytoin.
EstramustineThe serum concentration of Phenytoin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Phenytoin can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Phenytoin can be decreased when it is combined with Estrone.
Estrone sulfateThe metabolism of Estrone sulfate can be increased when combined with Phenytoin.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Phenytoin.
Etacrynic acidPhenytoin may decrease the diuretic activities of Etacrynic acid.
EthanolPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenytoin.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be increased when combined with Phenytoin.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
EthosuximideThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Phenytoin.
Ethyl biscoumacetatePhenytoin may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenytoin.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Phenytoin.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Phenytoin.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Phenytoin.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Phenytoin.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Phenytoin.
EtodolacThe metabolism of Etodolac can be increased when combined with Phenytoin.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenytoin.
EtonogestrelThe metabolism of Etonogestrel can be increased when combined with Phenytoin.
EtoperidoneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Phenytoin.
EtoposideThe serum concentration of Phenytoin can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Phenytoin.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Phenytoin.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Phenytoin.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Phenytoin.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Phenytoin.
EzogabineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ezogabine.
FamciclovirThe metabolism of Famciclovir can be increased when combined with Phenytoin.
FamotidineThe metabolism of Famotidine can be increased when combined with Phenytoin.
FelbamateThe risk or severity of adverse effects can be increased when Phenytoin is combined with Felbamate.
FelodipineThe metabolism of Felodipine can be increased when combined with Phenytoin.
FelodipineThe serum concentration of Phenytoin can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Phenytoin.
FendilineThe serum concentration of Phenytoin can be increased when it is combined with Fendiline.
FenfluramineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fenfluramine.
FenofibrateThe metabolism of Fenofibrate can be increased when combined with Phenytoin.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Phenytoin.
FentanylThe serum concentration of Phenytoin can be increased when it is combined with Fentanyl.
FesoterodineThe metabolism of Fesoterodine can be increased when combined with Phenytoin.
FexofenadineThe serum concentration of Phenytoin can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fexofenadine.
FidaxomicinThe serum concentration of Phenytoin can be increased when it is combined with Fidaxomicin.
FinasterideThe metabolism of Finasteride can be increased when combined with Phenytoin.
FingolimodThe metabolism of Fingolimod can be increased when combined with Phenytoin.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Phenytoin.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Phenytoin.
FloxuridineThe serum concentration of Phenytoin can be increased when it is combined with Floxuridine.
FluconazoleThe metabolism of Phenytoin can be decreased when combined with Fluconazole.
FlucytosineThe serum concentration of Phenytoin can be increased when it is combined with Flucytosine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Phenytoin.
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Phenytoin.
FlumazenilThe serum concentration of Phenytoin can be increased when it is combined with Flumazenil.
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Phenytoin.
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Phenytoin.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Phenytoin.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Phenytoin.
FlunitrazepamThe serum concentration of Phenytoin can be increased when it is combined with Flunitrazepam.
FlunitrazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Flunitrazepam.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Phenytoin.
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Phenytoin.
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Phenytoin.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Phenytoin.
FluorouracilThe serum concentration of Phenytoin can be increased when it is combined with Fluorouracil.
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Phenytoin.
FluoxetineThe serum concentration of Phenytoin can be increased when it is combined with Fluoxetine.
FluoxetineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluoxetine.
FlupentixolThe serum concentration of Phenytoin can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Phenytoin is combined with Flupentixol.
FluphenazineThe serum concentration of Phenytoin can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Phenytoin.
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Phenytoin.
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Phenytoin.
FlurazepamThe serum concentration of Phenytoin can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Flurazepam.
FlurbiprofenThe metabolism of Flurbiprofen can be increased when combined with Phenytoin.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenytoin.
FlutamideThe metabolism of Flutamide can be increased when combined with Phenytoin.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Phenytoin.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluticasone Propionate.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Phenytoin.
FluvastatinThe metabolism of Phenytoin can be decreased when combined with Fluvastatin.
FluvoxamineThe serum concentration of Phenytoin can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluvoxamine.
Folic AcidThe serum concentration of Phenytoin can be decreased when it is combined with Folic Acid.
FormoterolThe metabolism of Formoterol can be increased when combined with Phenytoin.
FosamprenavirThe serum concentration of Phenytoin can be decreased when it is combined with Fosamprenavir.
FosamprenavirThe metabolism of Fosamprenavir can be increased when combined with Phenytoin.
FosaprepitantThe serum concentration of Phenytoin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Phenytoin.
FulvestrantThe metabolism of Fulvestrant can be increased when combined with Phenytoin.
FurosemidePhenytoin may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Phenytoin can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenytoin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Phenytoin is combined with gabapentin enacarbil.
GalantamineThe metabolism of Galantamine can be increased when combined with Phenytoin.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Phenytoin.
GavestinelThe metabolism of Gavestinel can be increased when combined with Phenytoin.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Phenytoin.
GefitinibThe serum concentration of Phenytoin can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Gemfibrozil can be increased when combined with Phenytoin.
GenisteinThe serum concentration of Phenytoin can be increased when it is combined with Genistein.
GliclazideThe metabolism of Gliclazide can be increased when combined with Phenytoin.
GlimepirideThe metabolism of Glimepiride can be increased when combined with Phenytoin.
GlipizideThe metabolism of Glipizide can be increased when combined with Phenytoin.
GlucosamineThe metabolism of Glucosamine can be increased when combined with Phenytoin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Phenytoin.
GlyburideThe metabolism of Glyburide can be increased when combined with Phenytoin.
GlyburideThe serum concentration of Phenytoin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Phenytoin can be increased when it is combined with Glycerol.
GlyphosateThe serum concentration of Phenytoin can be increased when it is combined with Glyphosate.
Gramicidin DThe serum concentration of Phenytoin can be increased when it is combined with Gramicidin D.
GranisetronThe metabolism of Granisetron can be increased when combined with Phenytoin.
GrepafloxacinThe metabolism of Grepafloxacin can be increased when combined with Phenytoin.
GrepafloxacinThe serum concentration of Phenytoin can be increased when it is combined with Grepafloxacin.
GriseofulvinThe serum concentration of Phenytoin can be increased when it is combined with Griseofulvin.
GuanfacineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Phenytoin.
HalofantrineThe metabolism of Halofantrine can be increased when combined with Phenytoin.
HaloperidolThe serum concentration of Phenytoin can be increased when it is combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Phenytoin is combined with Haloperidol.
HaloproginThe serum concentration of Phenytoin can be increased when it is combined with Haloprogin.
HalothaneThe serum concentration of Phenytoin can be increased when it is combined with Halothane.
HalothaneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Phenytoin.
HexetidineThe serum concentration of Phenytoin can be increased when it is combined with Hexetidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Phenytoin.
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Phenytoin.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Phenytoin.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Phenytoin.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Phenytoin.
HydrocortisoneThe serum concentration of Phenytoin can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenytoin.
Hydroxyamphetamine hydrobromideThe serum concentration of Phenytoin can be decreased when it is combined with Hydroxyamphetamine hydrobromide.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be increased when combined with Phenytoin.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
HydroxyzineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Hydroxyzine.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Phenytoin.
IbuprofenThe metabolism of Ibuprofen can be increased when combined with Phenytoin.
IdarubicinThe metabolism of Idarubicin can be increased when combined with Phenytoin.
IdelalisibThe serum concentration of Phenytoin can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Phenytoin.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Phenytoin.
IloperidoneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Phenytoin.
ImatinibThe metabolism of Phenytoin can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Phenytoin can be increased when it is combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be increased when combined with Phenytoin.
IndacaterolThe metabolism of Indacaterol can be increased when combined with Phenytoin.
IndalpineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Indalpine.
IndapamideThe metabolism of Indapamide can be increased when combined with Phenytoin.
IndinavirThe metabolism of Indinavir can be increased when combined with Phenytoin.
IndinavirThe serum concentration of Phenytoin can be decreased when it is combined with Indinavir.
indisulamThe metabolism of indisulam can be increased when combined with Phenytoin.
IndomethacinThe serum concentration of Phenytoin can be increased when it is combined with Indomethacin.
IndomethacinThe metabolism of Indomethacin can be increased when combined with Phenytoin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be increased when combined with Phenytoin.
IrbesartanThe metabolism of Phenytoin can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Phenytoin resulting in a loss in efficacy.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Phenytoin resulting in a loss in efficacy.
IsavuconazoniumThe metabolism of Phenytoin can be decreased when combined with Isavuconazonium.
IsoconazoleThe serum concentration of Phenytoin can be increased when it is combined with Isoconazole.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Phenytoin.
IsoniazidThe metabolism of Phenytoin can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be increased when combined with Phenytoin.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be increased when combined with Phenytoin.
IsradipineThe metabolism of Isradipine can be increased when combined with Phenytoin.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Phenytoin.
ItraconazoleThe serum concentration of Phenytoin can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Phenytoin.
IvacaftorThe serum concentration of Phenytoin can be increased when it is combined with Ivacaftor.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Phenytoin.
IvermectinThe metabolism of Ivermectin can be increased when combined with Phenytoin.
IvermectinThe serum concentration of Phenytoin can be increased when it is combined with Ivermectin.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Phenytoin.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Phenytoin.
KetamineThe serum concentration of Phenytoin can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenytoin.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Phenytoin.
KetoconazoleThe metabolism of Ketoconazole can be increased when combined with Phenytoin.
KetoconazoleThe serum concentration of Phenytoin can be increased when it is combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be increased when combined with Phenytoin.
LacidipineThe serum concentration of Phenytoin can be increased when it is combined with Lacidipine.
LacosamideThe serum concentration of Lacosamide can be decreased when it is combined with Phenytoin.
LamotrigineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Lamotrigine.
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Phenytoin.
LansoprazoleThe serum concentration of Phenytoin can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Phenytoin.
LapatinibThe serum concentration of Phenytoin can be increased when it is combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be increased when combined with Phenytoin.
LeflunomideThe metabolism of Phenytoin can be decreased when combined with Leflunomide.
LenvatinibThe metabolism of Lenvatinib can be increased when combined with Phenytoin.
LercanidipineThe serum concentration of Phenytoin can be increased when it is combined with Lercanidipine.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Phenytoin.
LesinuradThe metabolism of Lesinurad can be increased when combined with Phenytoin.
LetrozoleThe metabolism of Letrozole can be increased when combined with Phenytoin.
LevetiracetamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Phenytoin.
LevocabastineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Levocetirizine.
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Phenytoin.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Phenytoin.
LevofloxacinThe serum concentration of Phenytoin can be increased when it is combined with Levofloxacin.
LevomefolateThe serum concentration of Phenytoin can be decreased when it is combined with Levomefolate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenytoin.
LevomilnacipranThe risk or severity of adverse effects can be increased when Phenytoin is combined with Levomilnacipran.
LevonorgestrelThe metabolism of Levonorgestrel can be increased when combined with Phenytoin.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenytoin.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Phenytoin.
LicofeloneThe metabolism of Licofelone can be increased when combined with Phenytoin.
LidocaineThe serum concentration of Phenytoin can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Phenytoin.
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Phenytoin.
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Phenytoin.
LisdexamfetamineThe serum concentration of Phenytoin can be decreased when it is combined with Lisdexamfetamine.
LisinoprilThe serum concentration of Phenytoin can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be increased when combined with Phenytoin.
LithiumThe risk or severity of adverse effects can be increased when Phenytoin is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Phenytoin.
LomitapideThe metabolism of Lomitapide can be increased when combined with Phenytoin.
LomitapideThe serum concentration of Phenytoin can be increased when it is combined with Lomitapide.
LoperamideThe metabolism of Loperamide can be increased when combined with Phenytoin.
LoperamideThe serum concentration of Phenytoin can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Phenytoin.
LopinavirThe serum concentration of Phenytoin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Phenytoin can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Loratadine.
LorazepamThe serum concentration of Phenytoin can be increased when it is combined with Lorazepam.
LorazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Lorazepam.
LorcaserinThe metabolism of Lorcaserin can be increased when combined with Phenytoin.
LornoxicamThe metabolism of Lornoxicam can be increased when combined with Phenytoin.
LosartanThe metabolism of Losartan can be increased when combined with Phenytoin.
LosartanThe serum concentration of Phenytoin can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Phenytoin.
LovastatinThe metabolism of Phenytoin can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenytoin.
Lu AA21004The risk or severity of adverse effects can be increased when Phenytoin is combined with Lu AA21004.
LuliconazoleThe serum concentration of Phenytoin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Phenytoin can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Phenytoin.
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Phenytoin.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Phenytoin.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenytoin.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Phenytoin.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Phenytoin is combined with Magnesium Sulfate.
MalathionThe metabolism of Malathion can be increased when combined with Phenytoin.
ManidipineThe serum concentration of Phenytoin can be increased when it is combined with Manidipine.
MaprotilineThe serum concentration of Phenytoin can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Phenytoin.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Phenytoin.
MebendazoleThe serum concentration of Phenytoin can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Phenytoin.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be increased when combined with Phenytoin.
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Phenytoin.
Mefenamic acidThe metabolism of Mefenamic acid can be increased when combined with Phenytoin.
MefloquineThe metabolism of Mefloquine can be increased when combined with Phenytoin.
MefloquineThe serum concentration of Phenytoin can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Phenytoin can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Phenytoin.
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Phenytoin.
MeloxicamThe metabolism of Meloxicam can be increased when combined with Phenytoin.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Phenytoin.
MephentermineThe serum concentration of Phenytoin can be decreased when it is combined with Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Phenytoin.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenytoin.
MeprobamateThe serum concentration of Phenytoin can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Phenytoin is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenytoin.
MestranolThe metabolism of Mestranol can be increased when combined with Phenytoin.
MetaxaloneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Metaxalone.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Phenytoin.
MethadoneThe serum concentration of Phenytoin can be increased when it is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Phenytoin.
MethamphetamineThe serum concentration of Phenytoin can be decreased when it is combined with Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Phenytoin.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Phenytoin.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Phenytoin.
MethocarbamolThe risk or severity of adverse effects can be increased when Phenytoin is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenytoin.
MethotrexateThe serum concentration of Phenytoin can be decreased when it is combined with Methotrexate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Phenytoin.
MethoxsalenThe metabolism of Methoxsalen can be increased when combined with Phenytoin.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Phenytoin.
MethsuximideThe risk or severity of adverse effects can be increased when Phenytoin is combined with Methsuximide.
MethylphenidateThe serum concentration of Phenytoin can be increased when it is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Phenytoin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenytoin.
MethyltestosteroneThe metabolism of Methyltestosterone can be increased when combined with Phenytoin.
MetoprololThe serum concentration of Phenytoin can be increased when it is combined with Metoprolol.
MetoprololThe metabolism of Metoprolol can be increased when combined with Phenytoin.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Phenytoin.
MetyraponeThe serum concentration of Metyrapone can be decreased when it is combined with Phenytoin.
MetyrosinePhenytoin may increase the sedative activities of Metyrosine.
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Phenytoin.
MevastatinThe serum concentration of Phenytoin can be increased when it is combined with Mevastatin.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Phenytoin.
MianserinThe therapeutic efficacy of Phenytoin can be decreased when used in combination with Mianserin.
MianserinThe metabolism of Mianserin can be increased when combined with Phenytoin.
MibefradilThe metabolism of Mibefradil can be increased when combined with Phenytoin.
MibefradilThe serum concentration of Phenytoin can be increased when it is combined with Mibefradil.
MicafunginThe serum concentration of Phenytoin can be increased when it is combined with Micafungin.
MiconazoleThe serum concentration of Phenytoin can be increased when it is combined with Miconazole.
MiconazoleThe metabolism of Miconazole can be increased when combined with Phenytoin.
MidazolamThe serum concentration of Phenytoin can be increased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Midazolam.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Phenytoin.
MifepristoneThe metabolism of Phenytoin can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Phenytoin is combined with Milnacipran.
MiltefosineThe serum concentration of Phenytoin can be increased when it is combined with Miltefosine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
MirabegronThe metabolism of Mirabegron can be increased when combined with Phenytoin.
MirtazapinePhenytoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Phenytoin.
MitomycinThe serum concentration of Phenytoin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Phenytoin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Phenytoin can be decreased when it is combined with Mitoxantrone.
MivacuriumPhenytoin may decrease the neuromuscular blocking activities of Mivacurium.
MoclobemideThe metabolism of Moclobemide can be increased when combined with Phenytoin.
ModafinilThe serum concentration of Phenytoin can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be increased when combined with Phenytoin.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Phenytoin.
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Phenytoin.
MonensinThe serum concentration of Phenytoin can be increased when it is combined with Monensin.
MontelukastThe metabolism of Montelukast can be increased when combined with Phenytoin.
MorphineThe serum concentration of Phenytoin can be increased when it is combined with Morphine.
MorphineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Morphine.
muraglitazarThe metabolism of muraglitazar can be increased when combined with Phenytoin.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be increased when combined with Phenytoin.
MyxothiazolThe serum concentration of Phenytoin can be increased when it is combined with Myxothiazol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
NabiloneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Nabilone.
NafcillinThe serum concentration of Phenytoin can be decreased when it is combined with Nafcillin.
NaftifineThe serum concentration of Phenytoin can be increased when it is combined with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenytoin.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Phenytoin.
NaloxoneThe metabolism of Naloxone can be increased when combined with Phenytoin.
NaltrexoneThe serum concentration of Phenytoin can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be increased when combined with Phenytoin.
NaringeninThe serum concentration of Phenytoin can be increased when it is combined with Naringenin.
NatamycinThe serum concentration of Phenytoin can be increased when it is combined with Natamycin.
NateglinideThe metabolism of Nateglinide can be increased when combined with Phenytoin.
NefazodoneThe metabolism of Nefazodone can be increased when combined with Phenytoin.
NefazodoneThe serum concentration of Phenytoin can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Phenytoin can be decreased when it is combined with Nelfinavir.
NelfinavirThe metabolism of Nelfinavir can be increased when combined with Phenytoin.
NeostigmineThe serum concentration of Phenytoin can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Phenytoin can be increased when it is combined with Netupitant.
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Phenytoin.
NevirapineThe metabolism of Nevirapine can be increased when combined with Phenytoin.
NicardipineThe metabolism of Nicardipine can be increased when combined with Phenytoin.
NicardipineThe serum concentration of Phenytoin can be increased when it is combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be increased when combined with Phenytoin.
NicotineThe metabolism of Nicotine can be increased when combined with Phenytoin.
NifedipineThe serum concentration of Phenytoin can be increased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Phenytoin.
NiguldipineThe serum concentration of Phenytoin can be increased when it is combined with Niguldipine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Phenytoin.
NilotinibThe metabolism of Phenytoin can be decreased when combined with Nilotinib.
NiludipineThe serum concentration of Phenytoin can be increased when it is combined with Niludipine.
NilutamideThe metabolism of Nilutamide can be increased when combined with Phenytoin.
NilvadipineThe serum concentration of Phenytoin can be increased when it is combined with Nilvadipine.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Phenytoin.
NimesulideThe serum concentration of Phenytoin can be increased when it is combined with Nimesulide.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Phenytoin.
NimodipineThe serum concentration of Phenytoin can be increased when it is combined with Nimodipine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Phenytoin.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Phenytoin.
NisoldipineThe serum concentration of Phenytoin can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Phenytoin can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Phenytoin.
NitrendipineThe serum concentration of Phenytoin can be increased when it is combined with Nitrendipine.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenytoin.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Phenytoin.
NitroxolineThe serum concentration of Phenytoin can be increased when it is combined with Nitroxoline.
NorethisteroneThe metabolism of Norethisterone can be increased when combined with Phenytoin.
NorethisteroneThe serum concentration of Phenytoin can be decreased when it is combined with Norethisterone.
NorgestrelThe metabolism of Norgestrel can be increased when combined with Phenytoin.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Phenytoin.
NortriptylineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Nortriptyline.
NystatinThe serum concentration of Phenytoin can be increased when it is combined with Nystatin.
OlanzapineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Phenytoin.
OlaparibThe metabolism of Phenytoin can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be increased when combined with Phenytoin.
OlopatadineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Olopatadine.
OmbitasvirThe metabolism of Ombitasvir can be increased when combined with Phenytoin.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Phenytoin.
OmeprazoleThe serum concentration of Phenytoin can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenytoin.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Phenytoin.
OrlistatThe serum concentration of Phenytoin can be decreased when it is combined with Orlistat.
OrphenadrinePhenytoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Phenytoin.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Phenytoin.
OsimertinibThe serum concentration of Phenytoin can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Phenytoin.
OspemifeneThe metabolism of Ospemifene can be increased when combined with Phenytoin.
OxaprozinThe metabolism of Oxaprozin can be increased when combined with Phenytoin.
OxazepamThe serum concentration of Phenytoin can be increased when it is combined with Oxazepam.
OxazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Oxazepam.
OxcarbazepineThe serum concentration of the active metabolites of Oxcarbazepine can be reduced when Oxcarbazepine is used in combination with Phenytoin resulting in a loss in efficacy.
OxiconazoleThe serum concentration of Phenytoin can be increased when it is combined with Oxiconazole.
OxiconazoleThe metabolism of Oxiconazole can be increased when combined with Phenytoin.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenytoin.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Phenytoin.
OxybutyninThe metabolism of Oxybutynin can be increased when combined with Phenytoin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenytoin.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenytoin.
P-NitrophenolThe serum concentration of Phenytoin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe metabolism of Paclitaxel can be increased when combined with Phenytoin.
PaclitaxelThe serum concentration of Phenytoin can be increased when it is combined with Paclitaxel.
pafuramidineThe serum concentration of Phenytoin can be increased when it is combined with pafuramidine.
PalbociclibThe serum concentration of Phenytoin can be increased when it is combined with Palbociclib.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Phenytoin.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenytoin.
Palmitic AcidThe serum concentration of Phenytoin can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be increased when combined with Phenytoin.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Phenytoin.
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Phenytoin.
PantoprazoleThe serum concentration of Phenytoin can be increased when it is combined with Pantoprazole.
ParaldehydePhenytoin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Phenytoin.
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Phenytoin.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Phenytoin.
ParecoxibThe metabolism of Parecoxib can be increased when combined with Phenytoin.
ParicalcitolThe metabolism of Paricalcitol can be increased when combined with Phenytoin.
ParitaprevirThe metabolism of Paritaprevir can be increased when combined with Phenytoin.
ParoxetineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Paroxetine.
ParoxetineThe serum concentration of Phenytoin can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Phenytoin.
PentamidineThe serum concentration of Phenytoin can be increased when it is combined with Pentamidine.
PentamidineThe metabolism of Pentamidine can be increased when combined with Phenytoin.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenytoin.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenytoin.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Phenytoin.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Phenytoin.
PergolideThe metabolism of Pergolide can be increased when combined with Phenytoin.
PerhexilineThe serum concentration of Phenytoin can be increased when it is combined with Perhexiline.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Phenytoin.
PerindoprilThe serum concentration of Phenytoin can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be increased when combined with Phenytoin.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Phenytoin.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Phenytoin.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Phenytoin.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Phenytoin.
PhenacetinThe metabolism of Phenacetin can be increased when combined with Phenytoin.
PhenindionePhenytoin may increase the anticoagulant activities of Phenindione.
PhenobarbitalPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhenobarbitalThe serum concentration of Phenytoin can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be increased when combined with Phenytoin.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Phenytoin.
PhenprocoumonPhenytoin may increase the anticoagulant activities of Phenprocoumon.
PhentermineThe serum concentration of Phenytoin can be decreased when it is combined with Phentermine.
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Phenytoin.
PilocarpineThe metabolism of Pilocarpine can be increased when combined with Phenytoin.
PimecrolimusThe metabolism of Pimecrolimus can be increased when combined with Phenytoin.
PimozideThe serum concentration of Phenytoin can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Phenytoin is combined with Pimozide.
PinacidilThe metabolism of Pinacidil can be increased when combined with Phenytoin.
PinaveriumThe serum concentration of Phenytoin can be increased when it is combined with Pinaverium.
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Phenytoin.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenytoin.
PipotiazineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Pipotiazine.
PirenzepineThe serum concentration of Phenytoin can be increased when it is combined with Pirenzepine.
PiretanidePhenytoin may decrease the diuretic activities of Piretanide.
PiroxicamThe metabolism of Piroxicam can be increased when combined with Phenytoin.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Phenytoin.
PizotifenThe risk or severity of adverse effects can be increased when Phenytoin is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Phenytoin can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be increased when combined with Phenytoin.
PomalidomideThe risk or severity of adverse effects can be increased when Phenytoin is combined with Pomalidomide.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Phenytoin.
PonatinibThe serum concentration of Phenytoin can be increased when it is combined with Ponatinib.
PosaconazoleThe metabolism of Posaconazole can be increased when combined with Phenytoin.
PosaconazoleThe serum concentration of Phenytoin can be increased when it is combined with Posaconazole.
PramipexolePhenytoin may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Phenytoin.
PrasugrelThe metabolism of Prasugrel can be increased when combined with Phenytoin.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Phenytoin.
PravastatinThe serum concentration of Phenytoin can be increased when it is combined with Pravastatin.
PrazepamThe serum concentration of Phenytoin can be increased when it is combined with Prazepam.
PrazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Prazepam.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Phenytoin.
PrazosinThe serum concentration of Phenytoin can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Phenytoin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Phenytoin.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Phenytoin.
PrednisoneThe serum concentration of Phenytoin can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Phenytoin.
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Phenytoin.
PrenylamineThe serum concentration of Phenytoin can be increased when it is combined with Prenylamine.
PrilocaineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Prilocaine.
PrimaquineThe metabolism of Primaquine can be increased when combined with Phenytoin.
PrimidoneThe metabolism of Primidone can be increased when combined with Phenytoin.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Phenytoin.
ProbenecidThe serum concentration of Phenytoin can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Phenytoin.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenytoin.
ProgesteroneThe metabolism of Progesterone can be increased when combined with Phenytoin.
ProgesteroneThe serum concentration of Phenytoin can be decreased when it is combined with Progesterone.
ProguanilThe metabolism of Proguanil can be increased when combined with Phenytoin.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Phenytoin.
PromethazineThe serum concentration of Phenytoin can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Promethazine.
PropacetamolThe serum concentration of the active metabolites of Propacetamol can be reduced when Propacetamol is used in combination with Phenytoin resulting in a loss in efficacy.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Phenytoin.
PropafenoneThe serum concentration of Phenytoin can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenytoin.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Phenytoin.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Phenytoin.
PropranololThe metabolism of Propranolol can be increased when combined with Phenytoin.
PropranololThe serum concentration of Phenytoin can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Phenytoin can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Phenytoin.
PyrazinamideThe metabolism of Pyrazinamide can be increased when combined with Phenytoin.
PyridoxineThe metabolism of Phenytoin can be increased when combined with Pyridoxine.
PyrimethamineThe metabolism of Phenytoin can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Phenytoin.
QuercetinThe serum concentration of Phenytoin can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenytoin.
QuinacrineThe metabolism of Quinacrine can be increased when combined with Phenytoin.
QuinacrineThe serum concentration of Phenytoin can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Phenytoin.
QuinidineThe serum concentration of Phenytoin can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Phenytoin.
QuinineThe serum concentration of Phenytoin can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be increased when combined with Phenytoin.
RadicicolThe serum concentration of Phenytoin can be increased when it is combined with Radicicol.
RaloxifeneThe metabolism of Raloxifene can be increased when combined with Phenytoin.
RamelteonThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ramelteon.
RanitidineThe serum concentration of Phenytoin can be increased when it is combined with Ranitidine.
RanitidineThe metabolism of Ranitidine can be increased when combined with Phenytoin.
RanolazineThe serum concentration of Phenytoin can be increased when it is combined with Ranolazine.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Phenytoin.
RapacuroniumPhenytoin may decrease the neuromuscular blocking activities of Rapacuronium.
ReboxetineThe metabolism of Reboxetine can be increased when combined with Phenytoin.
ReboxetineThe serum concentration of Phenytoin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Phenytoin.
RegorafenibThe serum concentration of Phenytoin can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenytoin.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenytoin.
RepaglinideThe metabolism of Repaglinide can be increased when combined with Phenytoin.
ReserpineThe serum concentration of Phenytoin can be decreased when it is combined with Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Reserpine.
RetapamulinThe metabolism of Retapamulin can be increased when combined with Phenytoin.
RifabutinThe metabolism of Rifabutin can be increased when combined with Phenytoin.
RifampicinThe metabolism of Rifampicin can be increased when combined with Phenytoin.
RifampicinThe serum concentration of Phenytoin can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Phenytoin can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Phenytoin.
RilpivirineThe serum concentration of Phenytoin can be increased when it is combined with Rilpivirine.
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Phenytoin.
RimonabantThe metabolism of Rimonabant can be increased when combined with Phenytoin.
RiociguatThe metabolism of Riociguat can be increased when combined with Phenytoin.
RisedronateThe serum concentration of Phenytoin can be increased when it is combined with Risedronate.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenytoin.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Phenytoin.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenytoin.
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Phenytoin.
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Phenytoin.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Phenytoin.
RolapitantThe serum concentration of Phenytoin can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Phenytoin.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Phenytoin.
RopinirolePhenytoin may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Phenytoin.
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Phenytoin.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Phenytoin.
RotigotinePhenytoin may increase the sedative activities of Rotigotine.
RoxithromycinThe metabolism of Roxithromycin can be increased when combined with Phenytoin.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Phenytoin.
RuxolitinibThe metabolism of Ruxolitinib can be increased when combined with Phenytoin.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Phenytoin.
Salicylhydroxamic AcidThe serum concentration of Phenytoin can be increased when it is combined with Salicylhydroxamic Acid.
Salicylic acidThe serum concentration of Phenytoin can be increased when it is combined with Salicylic acid.
Salicylic acidThe metabolism of Salicylic acid can be increased when combined with Phenytoin.
SalmeterolThe metabolism of Salmeterol can be increased when combined with Phenytoin.
SaquinavirThe metabolism of Saquinavir can be increased when combined with Phenytoin.
SaquinavirThe serum concentration of Phenytoin can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Phenytoin.
ScopolamineThe serum concentration of Phenytoin can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenytoin.
SelegilineThe metabolism of Selegiline can be increased when combined with Phenytoin.
SelegilineThe serum concentration of Phenytoin can be increased when it is combined with Selegiline.
SelexipagThe metabolism of Selexipag can be increased when combined with Phenytoin.
SeratrodastThe metabolism of Seratrodast can be increased when combined with Phenytoin.
SertaconazoleThe serum concentration of Phenytoin can be increased when it is combined with Sertaconazole.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Phenytoin.
SertralineThe serum concentration of Phenytoin can be increased when it is combined with Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenytoin.
SibutramineThe metabolism of Sibutramine can be increased when combined with Phenytoin.
SildenafilThe metabolism of Sildenafil can be increased when combined with Phenytoin.
SilodosinThe metabolism of Silodosin can be increased when combined with Phenytoin.
SiltuximabThe serum concentration of Phenytoin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Phenytoin can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Phenytoin.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Phenytoin.
SimvastatinThe serum concentration of Phenytoin can be increased when it is combined with Simvastatin.
SinefunginThe serum concentration of Phenytoin can be increased when it is combined with Sinefungin.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Phenytoin.
SitagliptinThe metabolism of Sitagliptin can be increased when combined with Phenytoin.
SitaxentanThe metabolism of Sitaxentan can be increased when combined with Phenytoin.
Sodium NitriteThe risk or severity of adverse effects can be increased when Phenytoin is combined with Sodium Nitrite.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Phenytoin.
SolifenacinThe metabolism of Solifenacin can be increased when combined with Phenytoin.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Phenytoin.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Phenytoin.
SorafenibThe serum concentration of Phenytoin can be increased when it is combined with Sorafenib.
SpiramycinThe metabolism of Spiramycin can be increased when combined with Phenytoin.
SpironolactoneThe serum concentration of Phenytoin can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Phenytoin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Phenytoin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Phenytoin can be decreased when it is combined with Stiripentol.
StiripentolThe risk or severity of adverse effects can be increased when Phenytoin is combined with Stiripentol.
StreptozocinThe serum concentration of Phenytoin can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenytoin.
SulconazoleThe serum concentration of Phenytoin can be increased when it is combined with Sulconazole.
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Phenytoin.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Phenytoin.
SulfamoxoleThe metabolism of Sulfamoxole can be increased when combined with Phenytoin.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Phenytoin.
SulfinpyrazoneThe serum concentration of Phenytoin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Phenytoin can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenytoin.
SumatriptanThe serum concentration of Phenytoin can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Phenytoin.
SunitinibThe serum concentration of Phenytoin can be increased when it is combined with Sunitinib.
SuprofenThe metabolism of Suprofen can be increased when combined with Phenytoin.
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Phenytoin.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Phenytoin.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Phenytoin.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Phenytoin.
TacrineThe serum concentration of Phenytoin can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Phenytoin.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Phenytoin.
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Phenytoin.
TamoxifenThe serum concentration of Phenytoin can be decreased when it is combined with Tamoxifen.
TamsulosinThe metabolism of Tamsulosin can be increased when combined with Phenytoin.
TapentadolThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tapentadol.
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Phenytoin.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Phenytoin.
TasosartanThe metabolism of Tasosartan can be increased when combined with Phenytoin.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be increased when combined with Phenytoin.
Taurocholic AcidThe serum concentration of Phenytoin can be increased when it is combined with Taurocholic Acid.
TavaboroleThe serum concentration of Phenytoin can be increased when it is combined with Tavaborole.
TazaroteneThe metabolism of Tazarotene can be increased when combined with Phenytoin.
TegafurThe serum concentration of Phenytoin can be increased when it is combined with Tegafur.
TelaprevirThe serum concentration of Phenytoin can be increased when it is combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Phenytoin.
TelithromycinThe metabolism of Telithromycin can be increased when combined with Phenytoin.
TelmisartanThe serum concentration of Phenytoin can be increased when it is combined with Telmisartan.
TemazepamThe serum concentration of Phenytoin can be increased when it is combined with Temazepam.
TemazepamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Temazepam.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Phenytoin.
TemsirolimusThe serum concentration of Phenytoin can be increased when it is combined with Temsirolimus.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Phenytoin.
TenoxicamThe metabolism of Tenoxicam can be increased when combined with Phenytoin.
TerazosinThe serum concentration of Phenytoin can be increased when it is combined with Terazosin.
TerbinafineThe serum concentration of Phenytoin can be increased when it is combined with Terbinafine.
TerbinafineThe metabolism of Terbinafine can be increased when combined with Phenytoin.
TerconazoleThe serum concentration of Phenytoin can be increased when it is combined with Terconazole.
TerfenadineThe metabolism of Terfenadine can be increased when combined with Phenytoin.
TerfenadineThe serum concentration of Phenytoin can be increased when it is combined with Terfenadine.
TeriflunomideThe metabolism of Phenytoin can be decreased when combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be increased when combined with Phenytoin.
TesmilifeneThe serum concentration of Phenytoin can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be increased when combined with Phenytoin.
TestosteroneThe serum concentration of Phenytoin can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Phenytoin.
TetracyclineThe metabolism of Tetracycline can be increased when combined with Phenytoin.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Phenytoin.
ThalidomidePhenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Phenytoin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Phenytoin.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenytoin.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenytoin.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenytoin.
ThiotepaThe metabolism of Thiotepa can be increased when combined with Phenytoin.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenytoin.
ThymolThe serum concentration of Phenytoin can be increased when it is combined with Thymol.
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Phenytoin.
TiagabineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tiagabine.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Phenytoin resulting in a loss in efficacy.
TicagrelorThe serum concentration of Phenytoin can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Phenytoin can be increased when it is combined with Ticlopidine.
TiclopidineThe metabolism of Ticlopidine can be increased when combined with Phenytoin.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Phenytoin.
TimololThe metabolism of Timolol can be increased when combined with Phenytoin.
TinidazoleThe metabolism of Tinidazole can be increased when combined with Phenytoin.
TioconazoleThe serum concentration of Phenytoin can be increased when it is combined with Tioconazole.
TiotropiumThe metabolism of Tiotropium can be increased when combined with Phenytoin.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Phenytoin.
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Phenytoin.
TizanidineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tizanidine.
TocilizumabThe serum concentration of Phenytoin can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Phenytoin.
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Phenytoin.
TolcaponeThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tolcapone.
Tolfenamic AcidThe serum concentration of Phenytoin can be increased when it is combined with Tolfenamic Acid.
TolnaftateThe serum concentration of Phenytoin can be increased when it is combined with Tolnaftate.
TolterodineThe metabolism of Tolterodine can be increased when combined with Phenytoin.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Phenytoin.
TolvaptanThe serum concentration of Phenytoin can be increased when it is combined with Tolvaptan.
TopiramateThe serum concentration of Phenytoin can be increased when it is combined with Topiramate.
TopiramateThe risk or severity of adverse effects can be increased when Phenytoin is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Phenytoin.
TorasemidePhenytoin may decrease the diuretic activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Phenytoin.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Phenytoin.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Phenytoin.
TranilastThe serum concentration of Phenytoin can be increased when it is combined with Tranilast.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenytoin.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenytoin.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be increased when combined with Phenytoin.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Phenytoin.
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Phenytoin.
TretinoinThe metabolism of Tretinoin can be increased when combined with Phenytoin.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Phenytoin.
TriazolamThe serum concentration of Phenytoin can be increased when it is combined with Triazolam.
TriazolamThe risk or severity of adverse effects can be increased when Phenytoin is combined with Triazolam.
TrifluoperazineThe serum concentration of Phenytoin can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Phenytoin can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Phenytoin.
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Phenytoin.
TrimethoprimThe serum concentration of Phenytoin can be decreased when it is combined with Trimethoprim.
TrimetrexateThe serum concentration of Phenytoin can be increased when it is combined with Trimetrexate.
TrimipramineThe serum concentration of Phenytoin can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Triprolidine.
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Phenytoin.
TroleandomycinThe metabolism of Troleandomycin can be increased when combined with Phenytoin.
TroleandomycinThe serum concentration of Phenytoin can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be increased when combined with Phenytoin.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Phenytoin.
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Phenytoin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Phenytoin.
ValsartanThe metabolism of Phenytoin can be decreased when combined with Valsartan.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Phenytoin.
VanoxerineThe metabolism of Vanoxerine can be increased when combined with Phenytoin.
VardenafilThe metabolism of Vardenafil can be increased when combined with Phenytoin.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Phenytoin.
VenlafaxineThe metabolism of Venlafaxine can be increased when combined with Phenytoin.
VerapamilThe metabolism of Verapamil can be increased when combined with Phenytoin.
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Phenytoin.
VigabatrinThe serum concentration of Phenytoin can be decreased when it is combined with Vigabatrin.
VigabatrinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Vigabatrin.
VilanterolThe metabolism of Vilanterol can be increased when combined with Phenytoin.
VilazodoneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Vilazodone.
VinblastineThe metabolism of Vinblastine can be increased when combined with Phenytoin.
VinblastineThe serum concentration of Phenytoin can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Phenytoin.
VindesineThe serum concentration of Phenytoin can be decreased when it is combined with Vindesine.
VindesineThe metabolism of Vindesine can be increased when combined with Phenytoin.
VinorelbineThe metabolism of Vinorelbine can be increased when combined with Phenytoin.
VinorelbineThe serum concentration of Phenytoin can be increased when it is combined with Vinorelbine.
VismodegibThe metabolism of Vismodegib can be increased when combined with Phenytoin.
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Phenytoin.
VoriconazoleThe metabolism of Voriconazole can be increased when combined with Phenytoin.
VortioxetineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Vortioxetine.
WarfarinPhenytoin may increase the anticoagulant activities of Warfarin.
XimelagatranThe metabolism of Ximelagatran can be increased when combined with Phenytoin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Phenytoin.
XylometazolineThe serum concentration of Phenytoin can be increased when it is combined with Xylometazoline.
YohimbineThe metabolism of Yohimbine can be increased when combined with Phenytoin.
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Phenytoin.
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Phenytoin.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Phenytoin.
ZaltoprofenThe metabolism of Zaltoprofen can be increased when combined with Phenytoin.
ZiconotideThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be increased when combined with Phenytoin.
ZileutonThe metabolism of Zileuton can be increased when combined with Phenytoin.
ZimelidineThe risk or severity of adverse effects can be increased when Phenytoin is combined with Zimelidine.
ZimelidineThe serum concentration of Phenytoin can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Phenytoin can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Phenytoin.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Phenytoin.
ZomepiracThe metabolism of Zomepirac can be increased when combined with Phenytoin.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Phenytoin.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenytoin.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Phenytoin.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Phenytoin.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenytoin.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenytoin.
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Take with food to increase bioavailability and reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Mitiushin VM, Kozyreva EV: [Several types of mitochondrial ultrastructure in animal cell mitochondria and their relationship to energy production]. Tsitologiia. 1978 Apr;20(4):371-9. [PubMed:150666 ]
  2. Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M: A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004 Mar;11(3):244-52. [PubMed:15001403 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN1A
Uniprot ID:
P35498
Molecular Weight:
228969.49 Da
References
  1. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12. Epub 2005 Apr 1. [PubMed:15805193 ]
  2. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH: A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics. 2006 Oct;16(10):721-6. [PubMed:17001291 ]
  3. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M: Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010 Apr;9(4):413-24. doi: 10.1016/S1474-4422(10)70059-4. [PubMed:20298965 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36 Suppl 5:S8-13. [PubMed:8806399 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12. Epub 2005 Apr 1. [PubMed:15805193 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Komatsu T, Yamazaki H, Asahi S, Gillam EM, Guengerich FP, Nakajima M, Yokoi T: Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos. 2000 Nov;28(11):1361-8. [PubMed:11038165 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36 Suppl 5:S8-13. [PubMed:8806399 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Komatsu T, Yamazaki H, Asahi S, Gillam EM, Guengerich FP, Nakajima M, Yokoi T: Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos. 2000 Nov;28(11):1361-8. [PubMed:11038165 ]
  5. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74. [PubMed:9014207 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Chen J, Ohnmacht C, Hage DS: Studies of phenytoin binding to human serum albumin by high-performance affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 25;809(1):137-45. [PubMed:15282104 ]
  2. Ohnmacht CM, Chen S, Tong Z, Hage DS: Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 19;836(1-2):83-91. Epub 2006 Apr 18. [PubMed:16621742 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
  2. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23